The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
Clinical trial NCT05063682 · UNKNOWN
Trial details
- NCT number
- NCT05063682
- Sponsor
- Chembrain LTD
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-15
- Primary completion
- 2023-10-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.